Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.55 |
| ▸ | EGFR | P00533 | 5/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743309 | 0.91 | SRC (0.61) | SRCEGFRERBB2GAKMAP2K1 | |
| SCHEMBL24392117 | 0.87 | SRC (0.56) | SRCEGFRERBB2GAKMAP2K1 | |
| SCHEMBL14445513 | 0.86 | SRC (0.55) | SRCEGFRERBB2GAKMAP2K1 | |
| SCHEMBL4743752 | 0.79 | SRC (0.62) | SRCEGFRERBB2GAKMAP2K1 | |
| SCHEMBL15263585 | 0.78 | SRC (0.59) | SRCEGFRERBB2GAKMAP2K1 | |
| SCHEMBL5498230 | 0.78 | SRC (0.59) | SRCEGFRERBB2GAKMAP2K1 | |
| SCHEMBL29590073 | 0.78 | SRC (0.62) | SRCEGFRERBB2GAKABL1 | |
| SCHEMBL1893090 | 0.78 | SRC (0.62) | SRCEGFRERBB2GAKABL1 | |
| SCHEMBL15279141 | 0.78 | EGFR (0.62) | SRCEGFRERBB2GAKMAP2K1 | |
| SCHEMBL30080014 | 0.78 | SRC (0.59) | SRCEGFRERBB2GAKMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | SRC 1453/4885EGFR 3929/4885ERBB2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.